AR065874A1 - Compuestos de pirimidina hidrazida como inhibidores de pgds - Google Patents
Compuestos de pirimidina hidrazida como inhibidores de pgdsInfo
- Publication number
- AR065874A1 AR065874A1 ARP080101297A ARP080101297A AR065874A1 AR 065874 A1 AR065874 A1 AR 065874A1 AR P080101297 A ARP080101297 A AR P080101297A AR P080101297 A ARP080101297 A AR P080101297A AR 065874 A1 AR065874 A1 AR 065874A1
- Authority
- AR
- Argentina
- Prior art keywords
- heterocyclyl
- optionally substituted
- alkyl
- heteroaryl
- y1y2n
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Composicion farmacéutica que comprende el compuesto, y al uso del compuesto para tratar trastornos alérgicos y/o inflamatorios, particularmente trastornos tales como rinitis alérgica, asma y/o enfermedad pulmonar obstructiva cronica(COPD). Reivindicacion 1: Un compuesto de formula (1): en la que: R1 es alquilo (C1-6) opcionalmente sustituido una o más veces independientemente con halo, hidroxi, alcoxi (C1-6) o haloalcoxi (C1-4) o cicloalquilo (C3-6), arilo o heteroarilo, cadauno de ellos opcionalmente sustituido una o más veces independientemente con halo, alquilo (C1-6), hidroxi, alcoxi (C1-6), haloalquilo (C1-4) o haloalcoxi (C1-4); R2 es hidrogeno o alquilo (C1-4) opcionalmente sustituido una o más veces conhalogeno; R3 es hidrogeno, alquilo, arilo o heteroarilo, R4 es hidrogeno, cicloalquilo, arilo, heterociclilo, heteroarilo, arilsulfonilo, heteroarilsulfonilo, -C(=O)-NY1Y2, -C(=S)-NY1Y2, R5, -C(=O)-R5 o -C(=S)-R5, donde el resto arilo, heteroarilo oheterociclilo está opcionalmente sustituido una o más veces independientemente con R6, o R3 y R4 junto con el átomo de nitrogeno al que están unidos forman heterociclilo, heterociclenilo, heteroarilo, arilheterociclilo, arilheterociclenilo,heteroarilheterociclilo, heteroarilheterociclenilo, heterociclilheteroarilo o heterociclenilheteroarilo, cada uno de ellos opcionalmente sustituido una o más veces independientemente con R6; R5 es cicloalquilo, cicloalquenilo, arilo, heteroarilo,heterociclilo, heterociclenilo, o alcarilo multicíclico, cada uno de ellos opcionalmente sustituido una o más veces independientemente con R6; L1 es un enlace, -O-, -C(=O)-, -NH-C(=O)- o alquileno (C1-2) opcionalmente sustituido una o más veces conhalo; R6 es ciano, nitro, halo, hidroxi, carboxi, Y1Y2N-, Y1Y2N-C(=O)-, Y1Y2N-SO2-, acilo, aciloxi, alquilo, alquenilo, alquinilo, alcoxi, alcoxicarbonilo, alquiltio, alquilsulfinilo o alquilsulfonilo, cada uno de ellos opcionalmente sustituido unao más veces independientemente con: aciloxi, halo, alcoxi, haloalcoxi, hidroxi, carboxi, alcoxicarbonilo, Y1Y2N-, Y1Y2N-C(=O)-, Y1Y2N-SO2-, arilo, ariloxi, aroílo, heteroarilo, heteroariloxi, heteroaroílo, heterociclilo, heterociclenilo,cicloalquilo, cicloalquenilo o alcarilo multicíclico, cada uno de ellos opcionalmente sustituido una o más veces independientemente con alquilo, halo, haloalquilo, alcoxi, haloalcoxi, hidroxi, amino, alquilamino, dialquilamino, carboxi oalcoxicarbonilo, o arilo, heteroarilo, aroílo, heteroaroílo, ariloxi, heteroariloxi, heterociclilo, heterociclenilo, cicloalquilo, cicloalquenilo o alcarilo multicíclico, cada uno de ellos opcionalmente sustituido una o más veces independientementecon alquilo, haloalquilo, halo, alcoxi, haloalcoxi, hidroxi, carboxi, alcoxicarbonilo, Y1Y2N- o Y1Y2N-SO2-, donde el resto heterociclilo, heterociclenilo, cicloalquilo, cicloalquenilo o alcarilo multicíclico de R6 también está opcionalmentesustituido una o más veces independientemente con oxo; cada uno de Y1 e Y2 es independientemente: hidrogeno, alquilsulfonilo, aroílo, heteroaroílo o alquilo opcionalmente sustituido una o más veces independientemente con hidroxi, carboxi, halo,amino, alquilamino, dialquilamino, alcoxi, heterociclilo, arilo o heteroarilo, o Y1 e Y2 junto con el átomo de nitrogeno al que están unidos forman un heterociclilo; o un hidrato, solvato o N-oxido del mismo, o una sal farmacéuticamente aceptabledel mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90917107P | 2007-03-30 | 2007-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065874A1 true AR065874A1 (es) | 2009-07-08 |
Family
ID=39494539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101297A AR065874A1 (es) | 2007-03-30 | 2008-03-28 | Compuestos de pirimidina hidrazida como inhibidores de pgds |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8258130B2 (es) |
| EP (1) | EP2142516B1 (es) |
| JP (1) | JP5427769B2 (es) |
| KR (1) | KR20090125852A (es) |
| CN (1) | CN101646656B (es) |
| AR (1) | AR065874A1 (es) |
| AU (1) | AU2008232771B2 (es) |
| BR (1) | BRPI0809974A2 (es) |
| CA (1) | CA2682629C (es) |
| CL (1) | CL2008000911A1 (es) |
| DK (1) | DK2142516T3 (es) |
| ES (1) | ES2400622T3 (es) |
| IL (1) | IL200898A (es) |
| MA (1) | MA31326B1 (es) |
| MX (1) | MX2009009443A (es) |
| MY (1) | MY154895A (es) |
| NZ (1) | NZ579892A (es) |
| PA (1) | PA8774101A1 (es) |
| PE (1) | PE20090552A1 (es) |
| PT (1) | PT2142516E (es) |
| RU (1) | RU2464262C2 (es) |
| SG (1) | SG179437A1 (es) |
| TW (1) | TWI430994B (es) |
| WO (1) | WO2008121670A1 (es) |
| ZA (1) | ZA200906082B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2142516T3 (da) | 2007-03-30 | 2013-04-15 | Sanofi Sa | Pyrimidinhydrazidforbindelser i ders egenskab af pgds-inhibitorer |
| WO2009029632A1 (en) * | 2007-08-27 | 2009-03-05 | Helicon Therapeutics, Inc. | Therapeutic isoxazole compounds |
| NO2300013T3 (es) | 2008-05-21 | 2018-02-03 | ||
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| US8536185B2 (en) | 2008-09-22 | 2013-09-17 | Cayman Chemical Company, Incorporated | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases |
| CA2744563A1 (en) * | 2008-12-12 | 2010-06-17 | Ariad Pharmaceuticals, Inc. | Azaindole derivatives as kinase inhibitors |
| EP2266562A1 (en) * | 2009-06-23 | 2010-12-29 | Centre National de la Recherche Scientifique | Use of derivatives of indoles for the treatment of cancer |
| US8703808B2 (en) | 2009-06-23 | 2014-04-22 | Centre National De La Recherche Scientifique | Use of derivatives of indoles for the treatment of cancer |
| EP2486024B1 (en) | 2009-10-08 | 2015-04-22 | Sanofi | Phenyloxadiazole derivatives as pgds inhibitors |
| AT509045B1 (de) | 2010-01-29 | 2011-06-15 | Planta Naturstoffe Vertriebsges M B H | Verbindungen zur behandlung von asthma bronchiale |
| EP2576536B1 (en) | 2010-06-01 | 2016-09-14 | The University of Queensland | Haematopoietic-prostaglandin d2 synthase inhibitors |
| EA201391626A1 (ru) | 2011-05-04 | 2014-03-31 | Ариад Фармасьютикалз, Инк. | Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака |
| BR112014012868B1 (pt) | 2011-11-29 | 2019-12-17 | Syngenta Participations Ag | derivados de triazinona inseticidas, composição pesticida que os compreende, método para combater e controlar pragas e insetos da ordem hemiptera e material de propagação de plantas |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| RU2674028C2 (ru) * | 2013-08-14 | 2018-12-04 | Калвиста Фармасьютикалз Лимитед | Ингибиторы ферментов |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| EP3165093A1 (en) | 2015-11-05 | 2017-05-10 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| RU2018126105A (ru) | 2015-12-17 | 2020-01-17 | Астекс Терапьютикс Лимитед | Хинолин-3-карбоксамиды в качестве ингибиторов h-pgds |
| IL293304A (en) | 2016-05-31 | 2022-07-01 | Kalvista Pharmaceuticals Ltd | History of pyrazole as plasma kallikrein inhibitors |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| UY37764A (es) | 2017-06-13 | 2019-01-02 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds) |
| HRP20220367T1 (hr) | 2017-11-29 | 2022-05-27 | Kalvista Pharmaceuticals Limited | Oblici za doziranje koji sadrže plazmatski kalikrein inhibitor |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| US20210139507A1 (en) | 2017-12-13 | 2021-05-13 | Glaxosmithkline Intellectual Property Development Limited | Fused pyridines which act as inhibitors of h pgds |
| JP2022506850A (ja) | 2018-11-08 | 2022-01-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 化学化合物 |
| EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| CA3183214A1 (en) | 2020-06-19 | 2021-12-23 | Motoaki Baba | Condensed ring compounds that inhibit h-pgds |
| CN112375027B (zh) * | 2020-12-07 | 2023-03-31 | 中国药科大学 | 吲哚磺酰胺类衍生物及其医药用途 |
| WO2023113023A1 (ja) * | 2021-12-17 | 2023-06-22 | 佐藤製薬株式会社 | Ｈ－ｐｇｄｓを阻害するアザインドール誘導体 |
| CN116514769B (zh) * | 2022-01-21 | 2024-02-27 | 中国药科大学 | 4-羟基嘧啶-5-甲酰腙衍生物、制备方法、药物组合物和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6143173A (ja) * | 1984-08-06 | 1986-03-01 | Mitsui Petrochem Ind Ltd | 新規ピリミジン誘導体およびその製法 |
| JPS61140568A (ja) * | 1984-12-14 | 1986-06-27 | Mitsui Petrochem Ind Ltd | キナゾリン誘導体及びそれを有効成分とする血圧降下剤 |
| US5176132A (en) | 1989-05-31 | 1993-01-05 | Fisons Plc | Medicament inhalation device and formulation |
| RU2343148C2 (ru) * | 2002-02-01 | 2009-01-10 | Райджел Фармасьютикалз, Инк | Соединения 2,4-пиримидиндиаминов и их применение |
| KR20050035885A (ko) | 2002-08-16 | 2005-04-19 | 아벤티스 파마슈티칼스 인크. | 마이크로솜성 프로스타글란딘 ｅ 신타제 또는 조혈성 프로스타글란딘 ｄ 신타제의 활성을 감소시키는 능력에 대해 화합물 또는 제제를 검정하는 방법 |
| GB0222023D0 (en) | 2002-09-21 | 2002-10-30 | Aventis Pharma Ltd | Inhaler |
| HN2005000795A (es) * | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| JP2007051121A (ja) * | 2005-07-22 | 2007-03-01 | Taiho Yakuhin Kogyo Kk | プロスタグランジンｄ合成酵素を阻害するピリミジン化合物 |
| BRPI0718874A2 (pt) * | 2006-12-22 | 2015-06-23 | Novartis Ag | Compostos orgânicos |
| DK2142516T3 (da) | 2007-03-30 | 2013-04-15 | Sanofi Sa | Pyrimidinhydrazidforbindelser i ders egenskab af pgds-inhibitorer |
| BRPI0809498A2 (pt) * | 2007-04-02 | 2014-09-23 | Inst Oneworld Health | Compostos inibidores de cftr e seus usos |
-
2008
- 2008-03-27 DK DK08744426.1T patent/DK2142516T3/da active
- 2008-03-27 KR KR1020097022868A patent/KR20090125852A/ko not_active Application Discontinuation
- 2008-03-27 JP JP2010501206A patent/JP5427769B2/ja not_active Expired - Fee Related
- 2008-03-27 RU RU2009140149/04A patent/RU2464262C2/ru not_active IP Right Cessation
- 2008-03-27 MY MYPI20093870A patent/MY154895A/en unknown
- 2008-03-27 BR BRPI0809974-0A2A patent/BRPI0809974A2/pt not_active IP Right Cessation
- 2008-03-27 NZ NZ579892A patent/NZ579892A/en not_active IP Right Cessation
- 2008-03-27 SG SG2012015442A patent/SG179437A1/en unknown
- 2008-03-27 CA CA2682629A patent/CA2682629C/en not_active Expired - Fee Related
- 2008-03-27 EP EP08744426A patent/EP2142516B1/en active Active
- 2008-03-27 CN CN2008800100835A patent/CN101646656B/zh active Active
- 2008-03-27 AU AU2008232771A patent/AU2008232771B2/en not_active Ceased
- 2008-03-27 PE PE2008000555A patent/PE20090552A1/es not_active Application Discontinuation
- 2008-03-27 MX MX2009009443A patent/MX2009009443A/es active IP Right Grant
- 2008-03-27 ES ES08744426T patent/ES2400622T3/es active Active
- 2008-03-27 PT PT87444261T patent/PT2142516E/pt unknown
- 2008-03-27 WO PCT/US2008/058347 patent/WO2008121670A1/en active Application Filing
- 2008-03-28 AR ARP080101297A patent/AR065874A1/es unknown
- 2008-03-28 TW TW097111155A patent/TWI430994B/zh not_active IP Right Cessation
- 2008-03-28 CL CL200800911A patent/CL2008000911A1/es unknown
- 2008-03-28 PA PA20088774101A patent/PA8774101A1/es unknown
-
2009
- 2009-09-02 ZA ZA200906082A patent/ZA200906082B/xx unknown
- 2009-09-13 IL IL200898A patent/IL200898A/en not_active IP Right Cessation
- 2009-09-30 US US12/570,355 patent/US8258130B2/en active Active
- 2009-10-22 MA MA32299A patent/MA31326B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0809974A2 (pt) | 2014-10-07 |
| JP5427769B2 (ja) | 2014-02-26 |
| AU2008232771A1 (en) | 2008-10-09 |
| AU2008232771B2 (en) | 2012-12-20 |
| IL200898A (en) | 2013-12-31 |
| PE20090552A1 (es) | 2009-06-01 |
| US8258130B2 (en) | 2012-09-04 |
| TWI430994B (zh) | 2014-03-21 |
| KR20090125852A (ko) | 2009-12-07 |
| PA8774101A1 (es) | 2008-11-19 |
| ZA200906082B (en) | 2010-06-30 |
| CA2682629A1 (en) | 2008-10-09 |
| JP2010523494A (ja) | 2010-07-15 |
| CN101646656B (zh) | 2013-08-14 |
| DK2142516T3 (da) | 2013-04-15 |
| US20100048568A1 (en) | 2010-02-25 |
| RU2009140149A (ru) | 2011-05-10 |
| IL200898A0 (en) | 2010-05-17 |
| CA2682629C (en) | 2013-03-19 |
| PT2142516E (pt) | 2013-03-07 |
| ES2400622T3 (es) | 2013-04-11 |
| RU2464262C2 (ru) | 2012-10-20 |
| CL2008000911A1 (es) | 2008-10-03 |
| SG179437A1 (en) | 2012-04-27 |
| MX2009009443A (es) | 2009-09-14 |
| WO2008121670A1 (en) | 2008-10-09 |
| MY154895A (en) | 2015-08-14 |
| NZ579892A (en) | 2012-03-30 |
| EP2142516A1 (en) | 2010-01-13 |
| MA31326B1 (fr) | 2010-04-01 |
| TW200906802A (en) | 2009-02-16 |
| CN101646656A (zh) | 2010-02-10 |
| EP2142516B1 (en) | 2012-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065874A1 (es) | Compuestos de pirimidina hidrazida como inhibidores de pgds | |
| CO6321265A2 (es) | Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso | |
| AR056871A1 (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
| PE20190511A1 (es) | Piridinas sustituidas con heteroarilo y metodos de uso | |
| ES2688733T3 (es) | Combinaciones de antagonistas de trpv4 | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| SV2009003305A (es) | Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| CR11757A (es) | Compuestos de triazina como inhibidores mtor y quinasa pi3 | |
| AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
| AR054726A1 (es) | 2- fenil- indoles como antagonistas del receptor de la prostaglandina d2 | |
| AR065622A1 (es) | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona | |
| AR084408A1 (es) | Compuestos de purina y 7-deazapurina substituidos | |
| CO6251260A2 (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
| DOP2011000076A (es) | Derivados de heteroaril amidas y su uso como activadores de glucoquinasa | |
| AR087288A1 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a | |
| AR081577A1 (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| AR059064A1 (es) | Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer. | |
| AR074814A1 (es) | Pirimidinas sustituidas como antagonistas del receptor ccr2 y usos de las mismas en medicamentos. | |
| AR061101A1 (es) | Compuesto de fenil-triazolil- metoxi- arilo, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprende | |
| AR056103A1 (es) | Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1 | |
| RU2014121205A (ru) | Производные азолов | |
| AR059320A1 (es) | Composicion antitumorial que comprende un inhibidor de quinasas dependientes de ciclinas y un anticuerpo que inhibe un factor de crecimiento y/o un compuesto antimitotico | |
| AR081960A1 (es) | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica | |
| AR077534A1 (es) | Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |